Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
Edison Scientific announced an agreement to deploy the Edison AI Platform and Kosmos, Edison's AI scientist, across Pfizer’s biopharmaceutical research and development pipeline. The collaboration brings together Edison’s industry-leading AI capabilities with Pfizer’s scientific expertise and robust repositories of data across oncology, internal medicine, immunology, and more. Kosmos will access Pfizer’s data to support Pfizer’s scientists, inform critical decisions in R&D, and help accelerate the discovery of potential new medicines.
At the core of the collaboration is Kosmos’ ability to learn continuously, providing Pfizer with a compounding and proprietary intelligence advantage. Kosmos will develop integrated world models by combining industry-leading access to publicly available and proprietary data sources from Pfizer’s internal drug development efforts. Edison’s forward-deployed scientists and engineers will work with Pfizer research teams, building Kosmos into specific workflows and helping shape how research gets organized and how decisions get made.
“Pfizer has spent decades generating data about what works and what doesn’t work in human biology,” said Sam Rodriques, Ph.D., CEO of Edison Scientific. “That experience serves as the foundation for Kosmos, ensuring lessons from each program are maximized to inform other programs, with every experiment and clinical readout strengthening the entire system. At Pfizer’s scale, the opportunity to turn accumulated scientific experience into better decisions is extraordinary.”
About Edison Scientific
Edison Scientific builds AI agents that make medicines for humanity. Kosmos, Edison’s collaborative AI scientist, partners with R&D teams to support critical decisions and workflows, leverage their proprietary data, and bring innovations to market faster. Edison is a scientist-led company that was spun out of the nonprofit research lab FutureHouse in 2025, backed by $70M from Spark Capital, Triatomic Capital, and other investors.
To learn more, visit edisonscientific.com and follow the company on LinkedIn and X.
Media Contact
Thermal for Edison Scientific
press@edisonscientific.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261029187599/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
This Once-Hot AI Stock Now Looks Deeply Undervalued
3 Stocks to Sell and 3 Stocks to Buy for November
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
5 Stocks to Buy Trading at Big Discounts
United States